IDO1 and hepatocellular carcinoma: Based on the activity of immune checkpoint blockade in HCC, the mechanistic rationale for combining IDO inhibitors and immunotherapy, and the tolerability of this combination in other malignancies, we conducted a Phase I/II trial evaluating the safety and efficacy of BMS-986,205 in combination with nivolumab in unresectable HCC.